These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29261649)

  • 21. Cost-effectiveness analysis of introducing rotavirus vaccine into immunization program in Zhejiang province, China: A decision tree-Markov model study.
    Lv H; Chen F; Wang Y; Chen Y; Hu Y
    Hum Vaccin Immunother; 2023 Aug; 19(2):2217075. PubMed ID: 37455405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis.
    Diop A; Atherly D; Faye A; Lamine Sall F; Clark AD; Nadiel L; Yade B; Ndiaye M; Fafa Cissé M; Ba M
    Vaccine; 2015 May; 33 Suppl 1():A119-25. PubMed ID: 25919151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination.
    Clark A; Jauregui B; Griffiths U; Janusz CB; Bolaños-Sierra B; Hajjeh R; Andrus JK; Sanderson C
    Vaccine; 2013 Jul; 31 Suppl 3():C19-29. PubMed ID: 23777686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of a routine rotavirus vaccination programme in Indonesia.
    Wilopo SA; Kilgore P; Kosen S; Soenarto Y; Aminah S; Cahyono A; Ulfa M; Tholib A
    Vaccine; 2009 Nov; 27 Suppl 5():F67-74. PubMed ID: 19931723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of rotavirus vaccination in Albania.
    Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
    Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
    Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
    Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-Level Costing Data.
    Bar-Zeev N; Tate JE; Pecenka C; Chikafa J; Mvula H; Wachepa R; Mwansambo C; Mhango T; Chirwa G; Crampin AC; Parashar UD; Costello A; Heyderman RS; French N; Atherly D; Cunliffe NA;
    Clin Infect Dis; 2016 May; 62 Suppl 2(Suppl 2):S220-8. PubMed ID: 27059360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.
    Kim SY; Sweet S; Chang J; Goldie SJ
    BMC Infect Dis; 2011 Jun; 11():174. PubMed ID: 21679420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand.
    Rochanathimoke O; Riewpaiboon A; Praditsitthikorn N; Tharmaphornpilas P; Jiamsiri S; Thavorncharoensap M; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):811-819. PubMed ID: 34008471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
    Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact and cost-effectiveness of rotavirus vaccination in Bangladesh.
    Pecenka C; Parashar U; Tate JE; Khan JAM; Groman D; Chacko S; Shamsuzzaman M; Clark A; Atherly D
    Vaccine; 2017 Jul; 35(32):3982-3987. PubMed ID: 28623028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of Rotavirus vaccination in Vietnam.
    Kim SY; Goldie SJ; Salomon JA
    BMC Public Health; 2009 Jan; 9():29. PubMed ID: 19159483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health and economic impact of rotavirus vaccination in GAVI-eligible countries.
    Kim SY; Sweet S; Slichter D; Goldie SJ
    BMC Public Health; 2010 May; 10():253. PubMed ID: 20470426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pneumonia Prevention during a Humanitarian Emergency: Cost-effectiveness of Haemophilus Influenzae Type B Conjugate Vaccine and Pneumococcal Conjugate Vaccine in Somalia.
    Gargano LM; Hajjeh R; Cookson ST
    Prehosp Disaster Med; 2015 Aug; 30(4):402-11. PubMed ID: 26061190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost and cost-effectiveness of childhood vaccination against rotavirus in France.
    Melliez H; Levybruhl D; Boelle PY; Dervaux B; Baron S; Yazdanpanah Y
    Vaccine; 2008 Jan; 26(5):706-15. PubMed ID: 18166250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of a universal rotavirus immunization program in Japan.
    Sato T; Nakagomi T; Nakagomi O
    Jpn J Infect Dis; 2011; 64(4):277-83. PubMed ID: 21788701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
    Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
    Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness evaluation of a rotavirus vaccination program in Argentina.
    Martí SG; Alcaraz A; Valanzasca P; McMullen M; Standaert B; Garay U; Lepetic A; Gomez J
    Vaccine; 2015 Oct; 33(42):5684-5690. PubMed ID: 26303875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand.
    Luangasanatip N; Mahikul W; Poovorawan K; Cooper BS; Lubell Y; White LJ; Teerawattananon Y; Pan-Ngum W
    Vaccine; 2021 Mar; 39(9):1402-1414. PubMed ID: 33531197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.
    Standaert B; Parez N; Tehard B; Colin X; Detournay B
    Appl Health Econ Health Policy; 2008; 6(4):199-216. PubMed ID: 19382820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.